百家汇与凯杰(苏州)转化医学研究有限公司达成战略合作协议

       

       2014年10月29日,百家汇科技创业社区有限公司与QIAGEN凯杰(苏州)转化医学研究有限公司宣布双方达成了战略合作协议,共同努力加速从学术发现向实用医疗成果的转化,包括为患者开发更新更好的治疗和诊断手段。

        此次合作旨在将百家汇的创新药物开发经验和资源与凯杰的先进专业技术相结合,提升创新药物的开发速度、效率以及临床开发的成功率。

        据悉,此次合作是百家汇打造CRO联盟的一部分。近期,百家汇还将与多个国内外知名CRO公司建立战略合作,为生命科学领域创新创业者提供更好的服务。

       此次合作公告原文如下:

BioSciKin/Simcere and QIAGEN (Suzhou) TMC enters strategic partnership to accelerate academic discoveries into tangible health benefits

 

Nanjing and Suzhou, Oct. 29, 2014, BioSciKin and QIAGEN (Suzhou) Translational Medicine Co., Ltd have announced a strategic partnership in order to accelerate the translation of academic discoveries into tangible health benefits, including the development of new and better medications and diagnosis for patients in need. The strategic partnership will seek to bring together BioSciKin’s innovative drug development experience and resources, and QIAGEN’s cutting-edge technologies and expertise to accelerate the pace at which new drugs are discovered, as well as their efficacy and successful rate in clinical trials.

 

Dr. Jingwu Zang, CSO of Simcere Pharmaceutical Group and CEO of BioSciKin, commented on the promise of the strategic alignment, stating:

“This partnership is an excellent strategy to enable knowledge-based decision making and foster new collaborative ways of working to translate scientific discovery into high-value treatment with increasing development efficiencies. Collaborating with QIAGEN (Suzhou) TMC on discovery projects allows us to not only leverage our proven core expertise, but also enhance our capabilities to deliver the next generation of healthcare based on translational science, offering treatments or possible cures for areas of unmet medical need in China.”

 

Dr. Nick Zhang, General Manager of QIAGEN (Suzhou) TMC, added: “By combining the strengths of the BioSciKin with the biomarker expertise and companion diagnostic products development capabilities of QIAGEN (Suzhou) TMC, we are creating a new, efficient, streamlined model for drug development in China. In the analysis of data on clinical trials for non-small cell lung cancer drug development between 1998 and 2012, the success rate was 28% for all types of drugs. However, if the drug was guided by a companion diagnostic assay the success rate increased to 62%. Through our collaboration, we will be able to translate the highest-quality science and technologies into proven clinical success in an efficient manner under the ever increasing challenging environment of drug development.”

 

To be sure, there is an intrinsic need for drug companies (Rx) and diagnostic company (Dx) to work together closely to not only break new research and discovery about treating diseases, but also to be able to develop and commercialize new treatments and diagnostic methods so that personalized healthcare can be realized in real time (Translation medicine = Rx+Dx).

 

About BioSciKin (www.bioscikin.com):

Bioscikin Ltd. is an innovative drug development platform that originates and is separated from Simcere, a leading innovative pharmaceutical company in China. Bioscikin has three campuses in China and is fully committed to discover, invest and co-develop innovative drug programs globally. 

 

About QIAGEN (Suzhou) Translational Medicine Co., Ltd (www.transmedchina.com):

Located in bioBAY, the innovative life sciences cluster in Suzhou Industrial Park, QIAGEN (Suzhou) Translational Medicine Co., Ltd is the first such R&D company focused on translational medicine in China.  Aiming to accelerate personalized healthcare through translational science, QIAGEN (Suzhou) TMC provides our partners with fully integrated solutions from biomarker discovery and development, to Companion Diagnostics (CDx) and Point-of-Care (PoC) product development, and all the way to clinical testing and commercialization through:

1).      High quality patient samples/biobank access in China with Qiagen standardized sampling workflow.

2).      Fully integrated biomarker discovery and development platform providing one stop solution and a wide range of services including both gene- and protein-based biomarker testing with multi-modal technology.

3).      World-class bioinformatics platforms and applications for the analysis, interpretation, and reporting of “omics” data.

4).      Validated diagnostic assays using liquid and tissue biopsy for clinical trials and robust companion diagnostic kits for commercialization.

[关闭窗口]
Copyright © 2014 www.njbjh.com.cn
All Rights Reserved
版权所有:百家汇创业社区
[苏ICP备13043461号-1]